Both in Biotechnology
Inhibikase Therapeutics vs Fate Therapeutics
Over the past year IKT returned +3.2% and FATE returned +27.9%; their daily moves had a correlation of 0.25.
IKT +3.2% FATE +27.9%Growth of $1, one year, split-adjusted
| Metric | IKT | FATE |
|---|---|---|
| Price | $1.59 | $2.11 |
| Market cap | $221.9M | $252.8M |
| Today | −2.45% | +0.96% |
| 1 month | −24.3% | −9.4% |
| 6 months | −15.4% | +58.6% |
| Year to date | −22.4% | +114.7% |
| 1 year | +3.2% | +41.6% |
| Revenue growth (YoY) | — | +9.2% |
| Gross margin | — | 100.0% |
| Net margin | — | −1448.6% |
| P/E (TTM) | — | — |
| Price / sales | — | 38.9× |
| Net cash | $159.0M | $153.8M |
| Dividend yield | — | — |
| Volatility (60d) | 52.1% | 60.6% |
| Short % of float | 17.6% | 10.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).